DLA Piper advised Iovance Biotherapeutics, Latham & Watkins advised the underwriters on the transaction. Iovance Biotherapeutics, Inc. (Iovance), a biotechnology company focused on innovating, developing and...
You must be a Standard 1 Year member to access this content.
DLA Piper advised Axsome Therapeutics on the offering. Axsome Therapeutics, Inc. (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
You must be a Standard 1 Year member to access this content.
DLA Piper advised Axsome Therapeutics on the deal. Axsome Therapeutics, Inc. (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
You must be a Standard 1 Year member to access this content.
DLA Piper advised Iovance Biotherapeutics in the deal. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced its definitive agreement with Clinigen Limited to acquire Proleukin® (aldesleukin), an interleukin-2...
You must be a Standard 1 Year member to access this content.
DLA Piper represented Axsome Therapeutics in the transaction. Axsome Therapeutics, a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced...
You must be a Standard 1 Year member to access this content.
